CAR-T therapy: what happens years later? new study tracks Long-Term risks
NCT ID NCT07474051
First seen Mar 22, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study follows about 178 people who previously received an experimental AvenCell CAR-T cell therapy for blood cancers or prostate cancer. Researchers will monitor participants for years to check for delayed side effects, such as new cancers, nerve disorders, or severe infections. The goal is to better understand the long-term safety and effectiveness of these treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Universitätsmedizin Berlin
Berlin, Germany
-
Klinikum der Universität (LMU) Muenchen
Munich, Germany
-
Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus
Dresden, Germany
-
Universitatsklinikum Ulm
Ulm, Germany
-
Universitätsklinikum Marburg
Marburg, Germany
Conditions
Explore the condition pages connected to this study.